|1.||Blom, Henk J: 57 articles (06/2015 - 05/2002)|
|2.||Selhub, Jacob: 57 articles (01/2015 - 02/2002)|
|3.||Tyagi, Suresh C: 55 articles (01/2015 - 01/2003)|
|4.||Tyagi, Neetu: 35 articles (10/2014 - 07/2005)|
|5.||Hultberg, Björn: 30 articles (01/2013 - 01/2002)|
|6.||Herrmann, Wolfgang: 29 articles (03/2013 - 08/2003)|
|7.||Verhoef, Petra: 29 articles (02/2012 - 08/2002)|
|8.||Wyse, Angela T S: 27 articles (10/2014 - 06/2002)|
|9.||Jakubowski, Hieronim: 26 articles (12/2015 - 11/2004)|
|10.||Refsum, Helga: 26 articles (07/2015 - 01/2002)|
|1.||Cardiovascular Diseases (Cardiovascular Disease)
09/07/2015 - "Determination of homocysteine (HcySH) is highly beneficial in human physiology and pathophysiology for diagnosis and prognosis of cardiovascular diseases (CVD). "
10/15/2005 - "Homocysteine levels that best discriminated between cardiovascular disease and gold-standard populations were 10.85 micromol/L in men (sensitivity 58%, specificity 68%), and 9.57 micromol/L in women (sensitivity 50%, specificity 81%). "
11/01/2001 - "Pending the outcome of such trials, measurement of plasma homocysteine concentrations in people at high risk of cardiovascular disease may help to identify patients who could benefit from more intensive treatment of classical cardiovascular risk factors. "
03/01/2011 - "The identification of a reference interval for total serum homocysteine concentration at these ages may help to identify those with a higher cardiovascular disease risk. "
01/01/2015 - "To determine whether homocysteine-lowering interventions, provided in patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events, as well as all-cause mortality and evaluate their safety. "
07/01/2000 - "These results suggest that plasma homocysteine is a potential risk factor of restenosis after PTCA, and therapeutic strategy targeted against hyperhomocysteinemia may be beneficial for preventing restenosis."
03/01/2003 - "Nutritional or pharmacologic interventions have been proposed in the treatment of hyperhomocysteinemia, while the results of large clinical trials designed to assess if lowering homocysteine levels is effective in reducing cardiovascular risk, are pending."
12/01/2014 - "Eligible studies should compare the prevalence of the MTHFR C677T mutation or hyperhomocysteinemia or the homocysteine levels between BCS or non-cirrhotic PVT patients and healthy controls or between cirrhotic patients with and without PVT. "
01/01/2013 - "There is an obvious contrast between the data from the epidemiological studies on hyperhomocysteinemia and the negative results of the homocysteine-lowering clinical trials. "
10/05/2012 - "This study established a pregnant rat model of hyperhomocysteinemia, in which blood plasma homocysteine concentrations were twice or three times greater than that of normal pregnant rats. "
|3.||Chronic Kidney Failure (Chronic Renal Failure)
09/01/2010 - "NAC administration resulted in a significant reduction in total homocysteine plasma concentrations in ESRD and healthy subjects, but had no effect on several other oxidative stress markers. "
06/05/2015 - "The relationship of systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP) with death, CVE, and progression to long-term dialysis was examined in 1099 patients with advanced CKD (eGFR≤30 ml/min per 1.7 3m(2); not receiving dialysis) who participated in the Homocysteine in Kidney and ESRD study. "
01/01/2015 - "However studies of homocysteine lowering in general and end-stage kidney disease (ESKD) populations have not demonstrated a reduction in cardiovascular event rates. "
10/01/2011 - "Here, we measured FGF-23 concentration in stored plasma samples from 1099 patients with advanced CKD who participated in The Homocysteine in Kidney and End Stage Renal Disease study. "
01/01/2009 - "Few clinical trials of homocysteine lowering have been conducted in persons with CKD before reaching end-stage renal disease. "
|4.||Vascular Diseases (Vascular Disease)
11/01/2000 - "However, the evidence needs to be strengthened by a systematic review of all comparable studies and the demonstration, in randomised trials, that lowering total homocysteine is followed by a significant reduction in atherothrombotic vascular disease. "
10/01/2004 - "Homocysteine is a risk factor for vascular diseases, and lowering of plasma total homocysteine (tHcy) may be beneficial for health. "
05/01/2000 - "To date, no randomized clinical trial has demonstrated that lowering of homocysteine levels is beneficial in terms of reducing the prevalence of vascular disease. "
02/01/1990 - "These data show that a substantial proportion of patients with early-onset vascular disease have impaired homocysteine metabolism, which may contribute to vascular disease, and that the impaired metabolism can be improved easily and without side effects."
12/01/2012 - "To elucidate this, a retrospective statistical analysis was done of data generated in the course of our study on homocysteine and vascular disease. "
08/01/2006 - "Lowering the risk of stroke is currently the most impressive effect of homocysteine-lowering-treatment and underlines the causal relationship. "
10/01/2015 - "The purpose of this study was to investigate the prevalence of high serum homocysteine level and relating factors, and the change over the 10 month period post-stroke. "
03/01/2015 - "Future randomized controlled trials may consider evaluating the effect of homocysteine lowering among stroke survivors with elevated homocysteine who are not on antiplatelet therapy."
01/01/2015 - "We therefore performed a study to elucidate the relationship between homocysteine levels and stroke prognosis. "
11/01/2014 - "Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies."
|1.||Folic Acid (Vitamin M)
|3.||Vitamin B 12 (Cyanocobalamin)
|6.||Vitamin B Complex (B Vitamins)
|8.||Vitamin B 6
|1.||Renal Dialysis (Hemodialysis)
|2.||Transplantation (Transplant Recipients)
|5.||Continuous Positive Airway Pressure